Tissue Procurement For Hematolymphoid Conditions
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Myeloproliferative Disorders
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Enrollment
- 15000
- Locations
- 1
- Primary Endpoint
- Tissue, blood, and body fluid samples collection for ongoing diagnostic, prognostic, or immune-monitoring studies
- Status
- Recruiting
- Last Updated
- 6 months ago
Overview
Brief Summary
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.
PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.
Detailed Description
OBJECTIVES: * Provide source of patient tissue, blood, and body fluid samples for ongoing diagnostic, prognostic, or immune-monitoring studies. * Support and enhance translational, clinical and basic research for Lineberger Comprehensive Cancer Center (LCCC) members (and non-members who have an LCCC member as sponsor and collaborator) with IRB-approved studies. * Maintain responsible and appropriate policies and procedures that ensure good patient care and responsible conduct of research. * Address medical and legal issues, and protect participant and patient privacy and confidentiality. * Provide a responsible and uniform mechanism for the integrated coordination of the hemato-pathologist and surgeon or hematology/oncology staff, researcher, and protocol office to obtain appropriate specimens for researchers. * Support young investigators to obtain pilot data for grant funding. OUTLINE: Patients undergo tissue, blood, and body fluid collection during diagnostic or routine procedures for future correlative studies. Tissue samples may include, but are not limited to, lymph node or non-nodal biopsies, bone marrow biopsy and/or aspirate, blood and serum, and buccal swabs for germline DNA analysis.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Tissue, blood, and body fluid samples collection for ongoing diagnostic, prognostic, or immune-monitoring studies
Time Frame: 30 years
Development of a centralized, quality-controlled, quality-assured facility for the procurement, processing, storage, and distribution of normal and malignant tissue specimens and corresponding blood specimens
Time Frame: 30 years